Bioequivalence, pharmacokinetic and pharmacodynamic response to combined extended release formulations of felodipine and metoprolol in healthy volunteers

European Journal of Clinical Pharmacology

Volumn 52, Issue 6, 1997, Pages 471-477

  Aberg J ^a   Abrahamsson, B ^a   Grind, M ^a   Nyberg, G ^a   Olofsson, B ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

Combined extended release formulation; Felodipine; Healthy volunteers; Metoprolol

Indexed keywords

FELODIPINE; METOPROLOL;

ADULT; ARTICLE; BIOAVAILABILITY; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; FATIGUE; FLUSHING; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; SIDE EFFECT; VERTIGO; VOLUNTEER;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; ANTIHYPERTENSIVE AGENTS; AREA UNDER CURVE; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DELAYED-ACTION PREPARATIONS; DRUG INTERACTIONS; FELODIPINE; FEMALE; HEART RATE; HUMANS; MALE; METABOLIC CLEARANCE RATE; METOPROLOL; MIDDLE AGED; THERAPEUTIC EQUIVALENCY;

EID: 0030773341     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050321     Document Type: Article

References (23)

1. Wingstrand K, Abrahamsson B, Edgar B (1990) Bioavailability from felodipine extended release tablets with different dissolution properties. Int J Pharm 60: 151-156
2. Blyckert E, Wingstrand K, Edgar B, Lidman K (1990) Plasma concentration profiles and antihypertensive effect of conventional and extended release felodipine tablets. Br J Clin Pharmacol 29: 39-45
3. Sandberg A, Abrahamsson B, Regårdh C-G, Wieselgren I, Bergstrand R (1990) Pharmacokinetic and biopharmaceutic aspects of once daily treatment with metoprolol CR/ZOK: a review article. J Clin Pharmacol 30: S2-16
4. Dahlöf B, Hosie J on behalf of the Swedish/UK study group (1993) Antihypertensive efficacy and tolerability of a new once-daily felodipine-metoprolol combination compared with each component alone. Blood Pressure 2 [Suppl 1]: 22-29
5. Dahlöf B, Jönsson L, Borgholst O, Ekblad G, Engstrand C, Grundstam I, Lindh A (1993) Improved antihypertensive efficacy of the felodipine-metoprolol extended-release tablet compared with each drug alone. Blood Pressure 2 [Suppl 1]: 37-45
6. Hoffman J on behalf of the German Multicentre Study Group (1993) Comparison of a felodipine-metoprolol tablet vs each component alone as antihypertensive therapy. Blood Pressure 2 [Suppl 1]: 30-36
7. Abrahamsson B, Edgar B, Lidman K, Wingstrand K (1993) Design and pharmacokinetics of the fixed combination a new extended-release combination tablet of felodipine and metoprolol. Blood Pressure 2 [Suppl 1]: 10-15
8. Otton SV, Crewe HK, Lennard MS, Tucker GT, Woods HF (1988) Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes. J Pharmacol Exper Ther 247: 242-247
9. Wahlund G, Nerme V, Abrahamsson T, Sjöquist PO (1990) The beta1- and beta2-adrenoceptor affinity and beta1-blocking potency of S- and R-metoprolol. Br J Pharmacol 99: 592-596
10. Åberg J, Edgar B, Grind M, Nyberg G (1995) Vasodilating properties and pharmacokinetics of S- and R-felodipine in man. J Clin Pharmacol 35: 938
11. Ahnoff M, Ervik M, Johansson L (1987) Comparison of high-selectivity gas chromatographic methods, including switching, for determination of felodipine in plasma. J Chromatog 394: 419-427
12. Soons PA, Roosenmalen MCM, Breimer DD (1990) Enantioselective determination of felodipine and other chiral dihydropyridine calcium entry blockers in human plasma. J Chromatogr 528: 343-356
13. Ervik M, Kylberg-Hansen K, Johansson L (1986) Determination of metoprolol in plasma and urine using high-resolution gas chromatoaraphy and electron capture detection. J Chromatogr 381: 168-174
14. 1-acid glyeoprotein column. Chromatography 500: 629-636
15. Rocha P, Guerret M, David D, Marchand X, Kahn JC (1990) Kinetics and hemodynamic effects of intravenous nicardipine modified by previous propranolol oral treatment. Cardiovasc Drugs Ther 4: 1525-1532
16. Schoors DF, Vercruysse I, Musch G, Massart DL, Dupont AG (1990) Influence of nicardipine on the pharmacokinetics and pharmacodynamics propranolol in healthy volunteers. Br J Clin Pharmacol 29: 497-501
17. Levine MA, Ogilvier RI, Leenen FH (1988) Pharmacokinetic and pharmacodynamic interactions between nisoldipine and propranolol. Clin Pharmacol Ther 43: 39-48
18. Smith SR, Wilkins MR, Jack DB, Kendall MJ, Laugher S (1987) Pharmacokinetic interactions between felodipine and metoprolol. Eur J Clin Pharmacol 31: 575-578
19. Åberg J, Bergstrand R, Edgar B (1991) The effect of felodipine on hepatic blood flow and antipyrine clearance. Clin Pharmacol Ther 49: 158
20. Soons PA, Mulders TMT, Uchida E, Schoemaker HC, Cohen AF, Breimer DD (1993) Stereoselective pharmacokinetics of oral felodipine and nitrendipine in healthy subjects: correlation with nifedipine pharmacokinetics. Eur J Clin Pharmacol 44: 163-169
21. Sandberg A, Abrahamsson B, Regårdh C-G (1993) Pharmacokinetics of metoprolol enantiomers after administration of the racemate and (s)-enantiomer as oral solutions and extended-release tablets. Drugs Investig 6: 320-329
22. Blyckert E, Edgar B, Elmfeldt D, Hedner T (1991) A population study of the pharmacokinetics of felodipine. Br J Clin Pharmacol 31: 15-24
23. Larsson M, Landahl S, Lundborg P, Regårdh C-G (1984) Pharmacokinetics of metoprolol in healthy, elderly, non-smoking individuals after a single dose and two weeks of treatment. Eur J Clin Pharmacol 27: 217-222